Long-term follow-up (22-33 months) after a single treatment with NX 1207 in patients with benign prostatic hyperplasia.

Trial Profile

Long-term follow-up (22-33 months) after a single treatment with NX 1207 in patients with benign prostatic hyperplasia.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2008

At a glance

  • Drugs Fexapotide (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Therapeutic Use
  • Sponsors Nymox Pharmaceutical Corporation
  • Most Recent Events

    • 31 Oct 2008 Results from this study were presented at the Western Section of the American Urological Association Meeting, according to a Nymox media release.
    • 26 Sep 2008 Results from this development program presented at the American Urological Association Meeting in Chicago, as reported in a Nymox media release.
    • 17 Sep 2008 Results presented at the 87th Annual Meeting of the South Central Section of the American Urological Association Meeting in September.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top